References Lancet Diabetes Endocrinology (2024) Efficacy and safety of coadministered onceweekly cagrilintide 2.4 mg with Semaglutide 2.4 mg in type 2 diabetes: phase 2 trial Lancet (2021) Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant cagrilintide with Semaglutide 2.4 mg: phase 1b trial Lancet (2021) Onceweekly cagrilintide for weight management: dosefinding phase 2 trial in overweight/obesity StatPearls (2025) Semaglutide: pharmacology, indications, and clinical use overview Cureus (2024) Semaglutide: risks and benefits review (PMC) WHO (2010) Best practices for injection and related procedures (WHO toolkit) SigmaAldrich (2016) Peptide Handling Guide: storage, reconstitution, and stability LibreTexts (2020) Intradermal and subcutaneous injections: clinical procedures CDC (2024) Vaccine administration: subcutaneous injection technique Additional Research and Background These sources provide related context and are not presented as support for a specific statement above

* Based on a clinical study conducted by Maraderm Skin Science Research Center with 21 adults aged 4257, from December 19, 2022 to January 20, 2023
Available at Telesford I, Schwartz H, Claxton G, et al
Above all, we prioritize a supportive environment, focusing on providing compassion and encouragement during your weight loss journey to help you succeed
So they're not the FDA approved versions, but when there's a shortage of a medication, the compounders are allowed to make these drugs to meet the shortage